alexa Global Control Of HIV, HCV And Infectious Diseases: India Is Not A Problem, But A Solution
ISSN: 2332-0877

Journal of Infectious Diseases & Therapy
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

6th Euro-Global Conference on Infectious Diseases
September 07-09, 2017 | Paris, France

Ishwar Gilada
Unison Medicare and Research Centre, India
Keynote: J Infect Dis Ther
DOI: 10.4172/2332-0877-C1-031
Abstract
The global AIDS Epidemic has completed 36 years of its devastating presence killing over 35 million people. Yet India has brought hope to millions, for making HIV- a chronic, manageable and affordable disorder. Last decade has witnessed astounding evolution in ART, from treating few to ‘Treat-All’ culminating in the WHO’s 90-90-90 by 2020 target, piggybacking on India’s strength. Fixed dose combination like anti-TB treatment, invented in India made ART affordable at 1% of innovators’ cost, accessible meets 80% of global ART and easier with single-dose regimen. Innovators called Indian Generics copy-cats. When ‘West copies East’, why apply different yardsticks? Indian pharma risked inviting litigations, circumvented patents using reverse engineering and steadily brought down cost, with 100% bio-equivalence. Cheapest FDC annual cost is down from US$ 10,439/- per patient to $69. ‘Magic’ cure for HIV is distant, but there are strategies and possibilities to end the epidemic. Indian ARVs are available including the newest Dolutegravir at 2% of innovator’s cost. For HCV cure, full course Sofosbuvir costs USD 84,000 globally, but in India its USD 1000 per patient through innovator’s voluntary licenses and USD 300 by patent violator, at 0.3% of International cost. Treating HIV-HCV is a public health imperative to prevent new transmissions, morbidity and mortality and delay will have grave public health consequences. Imagine a scenario of millions of HIV-HCV infections, minus India! Millions more would have died leading African continent towards extinction. The world recognized the Indian pharma strength in saving millions for decades from range of health issues only after HIV. In patents versus patients, the balance tilts towards patients to bridge the enormous gap. It’s a herculean task and will only be possible by an intensive and joint efforts of all including innovators. India will continue humanitarian mission to make life saving medicines affordable and accessible.
Biography

Ishwar Gilada is a Medical Doctor, specialized in Skin and STDs with special training in HIV management. He is the founder of India’s first private sector comprehensive HIV Care clinic, President of AIDS Society of India and is Secretary General of Peoples Health Org. India. He was the Jt. Sec. of National AIDS Committee, Govt of India (1995-97). He was the first to raise alarm against AIDS in 1985, is known for bringing India on AIDS control map, had started India’s first AIDS Clinic-1986 and has expertise in HIV care in resource-poor settings. He had trained several Doctors, Nurses and Social workers. He was Editor-Publisher of AIDS ASIA from 1993 to 2008. He has initiated, managed, supervised, evaluated over 40 HIV/AIDS projects in India, addressed over 3700 public meetings and training programs in India and abroad, has 280 scientific papers at conferences, written chapters in books on AIDS/STDs. He was consultant for American Foundation for AIDS Research (AmFAR), World Vision, USAID; has more than 65 awards to his credit including the "Outstanding Young Person of the World" –Glasgow in 1995 and Annemarie Madison Award-Germany in 1999 in Munich, Germany where he was termed as ‘the Indian Machinegun against AIDS’.

image PDF   |   image HTML
 

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version